Table 5. Recurrence Free Survival According to Treatment Era.

	Before 2003 n=169				After 2003 n=118
	%	% 5-year RFS	% 10-year RFS	p	%	% 5-year RFS	p
Age				.19			.26
22 – 50	27	43	37		38	33
≥ 50	73	33	29		62	47
Gender				.84			.94
Male	57	35	37		58	41
Female	43	36	44		42	43
# Hepatic Metastases				<.001			.07
1	38	51	51		25	58
2 – 4	46	34	25		47	43
5 – 7	11	5.3	5.3		18	24
≥ 8	5	0	0		10	25
Clinical Risk Score				<.001			.40
0 – 2	59	44	41		54	44
3 – 5	41	23	17		46	39
Margins (cm)				.14			.001
> 1 cm	44	40	38		31	60
≤ 1 cm	50	34	30		63	36
0 cm	6	30	0		6	13
Margins (mm)				.06			.02
> 1 mm	84	37	34		86	42
≤ 1 mm	10	23	23		8	55
0 cm	6	30	0		6	13
Size				.95			.16
< 5 cm	69	36	31		81	44
≥ 5 cm	31	35	33		19	30
Primary Lymph Nodes				<.01			.16
Negative	40	47	41		40	49
Positive	60	28	25		60	37
CEA Post-operative				.05			.43
< 5 ng/ml	68	38	35		80	43
≥ 5 ng/ml	32	30	25		20	33
Synchronous Disease				.08			.47
No	58	40	35		41	46
Yes	42	30	27		59	39
Prior Chemotherapy				.47			.95
No	34	37	33		20	43
Yes	66	33	28		81	41